The past three years have been some of the most eventful in memory for Taiwan‰Ûªs life sciences industry. Buoyed by a successful wave of…

The CEO of ASLAN Pharmaceuticals discusses the fundamental changes that need to occur in the treatment of serious illnesses, the advantages of…

Ask Indonesians about a bad experience in medical care and each will have a story to tell. The poor state of Indonesia‰Ûªs healthcare system has…

The latest details regarding Article 46, a key piece of legislation attached to the second-generation health insurance reform, were announced this…

In 2010, you began your last interview with us by mentioning two things: that because of the nature of this affiliate’s portfolio—with…

Ulf Wiinberg has been CEO of Lundbeck since June 2008. He was previously with Wyeth for 27 years. Ulf Wiinberg is a board member of EFPIA in Europe…

An in-depth viewpoint on the current taxation situation for pharmaceutical companies operating in Belgium today, looking at incentive programs and…

Donald Niesten and Omer Saka discuss the current dynamics of the healthcare and pharmaceutical sectors in Belgium, the challenges of entering the…

Smart Scale was recently certified and recognized for its international quality standards. What have been the main growth drivers? Our experience…

After just six months in the country, Novartis Australia’s new Managing Director offers his perspectives on the Australian pharmaceutical market and…

The managing director of Brussels Invest & Export discusses Belgium's unique attractiveness when it comes to the life sciences, and which…

As a Taiwanese national and Country Head of Novartis Taiwan, what is your opinion on the current state of the pharmaceutical industry in Taiwan, and…